LILRA4

LILRA4

LILRA4 詳細

Molecule Name
Leukocyte immunoglobulin-like receptor subfamily A member 4
分子の別称
LILRA4,CD85g,ILT7,ILT-7
Drug Development Progress
治験薬の数1
市販薬剤の数0
研究&開発段階Phase 2 Clinical
ターゲットの別称
ILT7,CD85g,Immunoglobulin-like transcript 7,LILRA4,Leukocyte Immunoglobulin Like Receptor A4,Leukocyte Immunoglobulin-Like Receptor, Subfamily A (With TM Domain), Member 4,CD85 Antigen-Like Family Member G,Leucocyte Ig-Like Receptor A4,Leukocyte Immunoglobulin-Like Receptor, Subfamily A (Without TM Domain), Member 4,Leukocyte Immunoglobulin-Like Receptor Subfamily A Member 4,CD85g Antigen,ILT-7
バックグランド
Leukocyte immunoglobulin-like receptor subfamily A member 4 (LILRA4/ILT7/CD85g) is a marker of plasmacytoid dendritic cells (pDCs), which are reported to be a major source of the abnormally high levels of IFNα associated with autoimmune diseases. Targeting LILRA4 with therapeutic antibodies to promote killing of these IFNα-producing pDCs is being investigated as a novel approach to alleviating the symptoms of autoimmune diseases. LILRA4 is an immunoglobulin-like protein preferentially expressed on the surface of human plasmacytoid dendritic cells (pDCs). It interacts with bone marrow stromal cell antigen 2 to control the Toll-like receptor (TLR) driven response by pDCs to viral infection. It may also be involved in modulating pDC-tumour interactions. pDCs are a source of the excess IFNα which drives autoimmune disease symptoms.

LILRA4 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
DaxdilimabMEDI-7734; VIB-7734; HZN-7734Phase 2 ClinicalHorizon Therapeutics PLC, Sbi Biotech Co Ltd
Acute Lung Injury; Alopecia Areata; Dermatomyositis; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Lupus Nephritis; Myositis; Polymyositis; Scleroderma, Systemic; Sjogren's Syndrome
詳細